



ultimovacs

Activating the immune system to fight cancer


Farmasidagene 2019

Øyvind Kongstun Arnesen, CEO Ultimovacs

Checkpoint inhibitors do not kill cancer cells

They make it possible for T-cells to do it

52 % 2 year Overall Survival in Malignant Melanoma



Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial; Lancet Oncology Volume 17, Issue 11

UV1 is a CD4 Activating, Universal Cancer Vaccine

UV1 is directed towards hTERT, which is expressed in 85-90% of all cancer indications


UV1 can be used in the general population without pre-screening of HLA

The UV1 vaccine consists of long peptides activating CD4 helper T lymphocytes

UV1 is easily manufactured, has a long shelf life and a low unit cost

Ease of clinical use, no complex hospital infrastructure required

Ultimovacs – Development Plan



Thank You

